Q4 2026 CBE filing targets echo-induced pacing risk
3 min read
8:37am on Wednesday 16th of September, 2026 AEST ~8am, 16th Sept, 26
EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.
- FDA alignment on proposed labelling pathway
- CBE PMA supplement planned for Q4 2026
- Echo-induced pacing risks to receive greater prominence
- No complication frequency or severity disclosed
- Update comes as US commercial rollout expands
FDA Supports Proposed WiSE Labelling Path
EBR Systems, Inc. (ASX:EBR) is preparing a regulatory update designed to put a known WiSE System risk more prominently in front of clinicians. The company says the US Food and Drug Administration has reviewed its plan to increase the visibility of echo-induced pacing risk and the clinical measures intended to mitigate it, and was aligned with the proposed path forward.
That alignment is useful, but it is not the same as approval of revised labelling. EBR plans to submit a Changes Being Effected, or CBE, Premarket Approval supplement in the fourth quarter of 2026. The company describes the CBE route as allowing safety-related labelling enhancements to be implemented while the supplement remains under FDA review.
Risk Mitigations Move to the Foreground
The proposed change is targeted rather than a redesign of the wireless cardiac pacing system. EBR says it wants mitigation strategies to be more prominent and easier for implanters to identify, with the aim of supporting procedural success and reducing the likelihood of complications.
The announcement does not quantify how often echo-induced pacing complications occur, how severe they have been, or precisely what wording will be added to the commercial labelling. Those omissions matter when assessing the practical significance of the update: the filing establishes that the risk warrants greater prominence, but does not provide a new safety dataset or indicate that the WiSE System is being withdrawn from use.
Submission Comes During US Commercial Expansion
EBR says the update is being pursued as commercial adoption of WiSE gathers momentum in the US. Its WiSE technology is currently available for sale only in the US and is designed to provide wireless endocardial stimulation of the left ventricle for patients requiring cardiac resynchronisation therapy.
For shareholders, the immediate regulatory signal is therefore mixed. FDA engagement has reduced uncertainty around the proposed process, while the need to elevate a known risk in product labelling highlights the importance of clinician training and implantation practice as the rollout scales. The next concrete milestone is the Q4 submission, followed by the content and timing of any final FDA response.
Bottom Line?
The FDA alignment clears a path for EBR to act quickly on safety labelling, but the investment significance will depend on the revised wording, subsequent FDA review and whether the update changes implantation practice or adoption.
Questions in the middle?
- When will EBR submit the CBE PMA supplement, and what exact labelling changes will it contain?
- How frequently and severely have echo-induced pacing complications occurred in clinical use?
- Will the revised risk disclosure affect physician training, implantation procedures or the pace of US adoption?
